[ 18 F]NP3‐627, a Candidate PET Imaging Agent Targeting the NLRP3 Inflammasome in the Central Nervous System
ChemMedChem · 16.02.2025 · 20 (4)
DOI: 10.1002/cmdc.202400816 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemMedChem, online erschienen am 27.11.2024. Verfasst von David M Whitehead und 12 weiteren Autor:innen. Beteiligte Einrichtung: Novartis Biomedical Research, Global Discovery Chemistry, Novartis Campus, WSJ-88.10.110, 4056, Basel, Switzerland. Hauptthemen laut MEDLINE: Positron-Emission Tomography, NLR Family, Pyrin Domain-Containing 3 Protein, Pyridazines, Inflammasomes. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben.
Abstract (Originalsprache)
We describe the identification of a candidate positron emission tomography (PET) imaging agent for the NLRP3 protein. NLRP3 plays a critical role in the immune system and has proven a difficult target for the development of imaging agents due to its low and cell‐specific expression profile. A recently described series of pyridazine‐based inhibitors, with improved permeability and brain‐penetration properties, was used as a starting point for the development of a suitable PET imaging agent. Optimization of affinity, non‐specific binding and pharmacokinetic properties led to the identification of aminopyridazine ( R )‐2‐(6‐((1‐cyclopropylpiperidin‐3‐yl)amino)pyridazin‐3‐yl)‐5‐fluoro‐3‐methylphenol ( 17 b ), which meets the preclinical profile of a successful imaging agent, and whose tritiated version demonstrated excellent specificity in a radioligand saturation binding assay, confirming its imaging potential. 18 F labeling led to [ 18 F]NP3‐627 , the proposed PET imaging agent.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Novartis Biomedical Research, Global Discovery Chemistry, Novartis Campus, WSJ-88.10.110, 4056, Basel, Switzerland.
- Novartis Biomedical Research, Immunology Research, Novartis Campus, WSJ-386, 4056, Basel, Switzerland.
- ETH Zurich, Institute of Pharmaceutical Sciences, Vladimir-Prelog Weg 4, 8093, Zurich, Switzerland.
ORCID-Profile: Christian Fischer, Emmanuelle Briard, Christopher J Farady, Klemens Kaupmann, Guillaume Lapointe, Angela Mackay, Lisa Reichert, Linjing Mu, Yves P Auberson
Zitieren
APA
Whitehead, D. M., Fischer, C., Briard, E., Farady, C. J., Graveleau, N., Karrer, J., Kaupmann, K., Lapointe, G., Mackay, A., Reichert, L., Wright, M., Mu, L., & Auberson, Y. P. (2025). [ 18 F]NP3‐627, a Candidate PET Imaging Agent Targeting the NLRP3 Inflammasome in the Central Nervous System. ChemMedChem, 20(4). https://doi.org/10.1002/cmdc.202400816
Vancouver
Whitehead DM, Fischer C, Briard E, Farady CJ, Graveleau N, Karrer J, et al. [ 18 F]NP3‐627, a Candidate PET Imaging Agent Targeting the NLRP3 Inflammasome in the Central Nervous System. ChemMedChem. 2025;20(4). doi:10.1002/cmdc.202400816
BibTeX
@article{Whitehead2025,
author = {Whitehead, David M and Fischer, Christian and Briard, Emmanuelle and Farady, Christopher J and Graveleau, Nadège and Karrer, Joel and Kaupmann, Klemens and Lapointe, Guillaume and Mackay, Angela and Reichert, Lisa and Wright, Michael and Mu, Linjing and Auberson, Yves P},
title = {[ 18 F]NP3‐627, a Candidate PET Imaging Agent Targeting the NLRP3 Inflammasome in the Central Nervous System},
journal = {ChemMedChem},
year = {2025},
volume = {20},
number = {4},
doi = {10.1002/cmdc.202400816}
}
EUVIMED